Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool February 17, 2010 Brian Orelli	$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%.
The Motley Fool May 19, 2010 Brian Orelli	A Potential Blockbuster Bites the Dust. Should You Worry? Despite the gloomy headlines, investors shouldn't be upset that Roche and Biogen Idec have decided to end development of ocrelizumab for rheumatoid arthritis.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool June 22, 2011 Brian Orelli	In-Licensing to the Rescue Abbott's latest deal could help shore things up.
The Motley Fool April 29, 2011 Brian Orelli	Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
The Motley Fool August 26, 2009 Brian Orelli	Small Change, Big Impact? A small difference in wording could have a huge effect on sales of Bristol-Myers Squibb's Orencia.
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool June 17, 2004 Brian Gorman	Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results.
The Motley Fool May 11, 2011 Brian Orelli	Abbott's Lucky Number Seven might be Abbott Labs' Humira's lucky number. The anti-inflammatory is up for approval in its seventh indication and the data looks pretty good.
The Motley Fool June 13, 2008 Brian Orelli	Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
The Motley Fool January 26, 2011 Brian Orelli	J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot.
The Motley Fool November 30, 2010 Brian Orelli	RNAi Is On Sale The novel technology looks more promising at these prices.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
The Motley Fool January 26, 2010 Brian Orelli	Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.
The Motley Fool June 12, 2008 Brian Orelli	Schering-Plough and J&J Score a Triple-Triple Schering-Plough and Johnson & Johnson present three phase 3 trials for a single drug, their anti-TNF medication golimumab.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool July 15, 2009 Brian Orelli	Less Inflammation From Abbott's Quarter Humira is headed back in the right direction.
The Motley Fool September 19, 2008 Brian Orelli	Skinning the Competition J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool April 21, 2011 Brian Orelli	Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool July 24, 2009 Brian Orelli	Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 10, 2004 David Nierengarten	The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market.
The Motley Fool July 29, 2011 Brian Orelli	Bristol-Myers Grows in the Wrong Places Bristol-Myers has a solid quarter, but Plavix and currency movements aren't important.
The Motley Fool September 20, 2010 Brian Orelli	Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time.
The Motley Fool November 1, 2004 Brian Gorman	Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes.